 |
|
|
|||||
Japan’s chief trade negotiator has defended a tariffs deal with the U.S., expressing respect for President Donald Trump and calling him a “tough negotiator.”Trade envoy Ryosei Akazawa noted that the pact setting on most Japanese exports to the U.S. at 15% was comparable to a deal between Washington and the European Union. Unlike the EU, Japan did not have to lower its tariffs on U.S. goods, he noted.Japan has also committed to investing $550 billion in U.S. projects.Trump initially set Japan’s tariff rate to increase by 25%.Critics in Japan had ridiculed Akazawa’s repeated trips to the U.S. to work toward a deal as a waste of taxpayer money, saying he should pitch a tent on the White House lawn.Akazawa said talks with his counterpart, U.S. Commerce Secretary Howard Lutnick, Trump and others in his administration were tense at first. By the time of his eighth trip, a rapport was established enabling the two sides to set an agreement by July.“President Trump was a tough negotiator, but I kept insisting, and he would listen graciously. I have all the respect for him,” he told reporters at the Foreign Correspondents’ Club of Japan. “It was a good round of negotiations.”“It goes without saying that, with any government negotiations, there will always be someone who says Japan lost out, no matter what,” Akazawa said.The double-digit tariffs Trump has imposed on imports from various nations were a bitter blow to Japan, a key U.S. ally in Asia. Tokyo especially objected to 25% tariffs Trump ordered for imports of steel and aluminum and automobiles.Japan’s economy depends heavily on exports. Shipments to the United States sank nearly 14% in August compared to a year earlier, the fifth straight month of declines, as auto exports were dented by the tariffs.U.S. tariffs on Japanese automobiles and auto parts are now set at 15%, way higher than the original 2.5%. Japanese automakers also produce many of the vehicles they sell in the U.S. in North America.The friction with the U.S. over tariffs was an added burden for Prime Minister Shigeru Ishiba’s administration. He is due to be replaced as leader of the ruling Liberal Democratic Party later this week.The Liberal Democrats have ruled Japan almost continuously since the 1950s but they have lost their majority in the lower house, which chooses the prime minister, and will need coalition partners.Akazawa brushed off concerns the U.S. understanding of the deal may differ from Japan’s. He said whoever becomes a next prime minister, Japan has an established tradition of respecting agreements, especially those forged with a foreign country. Yuri Kageyama is on Threads: https://www.threads.com/@yurikageyama Yuri Kageyama, AP Business Writer
Category:
E-Commerce
The United States has agreed to allow South Korean workers on short-term visas or a visa waiver program to help build industrial sites in America, Seoul’s Foreign Ministry said Wednesday.The announcement came weeks after South Korea flew home more than 300 of its nationals who had been detained in a massive immigration raid at a battery factory being built on Hyundai’s sprawling auto plant campus near Savannah, Georgia.The roundup, along with U.S. video footage showing Korean workers shackled at the hands, ankles and waist, fueled public outrage and a sense of betrayal in South Korea a key U.S. ally that had pledged hundreds of billions of dollars in U.S. investments just weeks earlier in hopes of avoiding the Trump administration’s steepest tariffs.The incident also triggered pent-up frustrations in Seoul over Washington’s failure to act on its long-standing request to improve the visa system for skilled Korean workers, even as the United States presses its ally to expand industrial investments.South Korean companies have been mostly relying on short-term visas or a visa waiver program called the Electronic System for Travel Authorization, or ESTA, to send workers needed to launch manufacturing sites and handle other setup tasks, a practice that had been largely tolerated for years.After bilateral visa talks Tuesday in Washington, South Korea’s Foreign Ministry said their American counterparts reaffirmed that South Korean companies can use B-1 short-term business visas or ESTAs to send workers to install, service and repair equipment needed for their projects in the United States. The statement was consistent with earlier remarks by South Korean Foreign Minister Cho Hyun, who, after traveling to Washington to negotiate the workers’ release, said that U.S. officials had agreed to allow them to return later to complete their work.South Korea has called for more fundamental steps, such as creating a new visa category to expand access for skilled workers. But U.S. officials at the Washington meeting said major changes would be difficult because of legislative constraints, according to a statement from the South Korean ministry.Most of the Korean workers detained in Georgia were employed by LG Energy Solution and its subcontractors and held ESTAs as well as other visas.LG said in a statement that it will “thoroughly prepare and work diligently to normalize the construction and operation of our factories in the United States.” Kim Tong-Hyung, Associated Press
Category:
E-Commerce
Several pharmaceutical companies have said they will sell drugs direct to patients in the U.S. and offered discounts following President Donald Trump’s calls to bring down drug prices and cut out “middlemen” like pharmacies, insurers and pharmacy benefit managers. The Trump administration announced on Tuesday plans to launch a government-run website called TrumpRx.gov in early 2026, offering reduced prices for prescription drugs. U.S. patients currently pay by far the most for prescription medicines, often nearly three times more than in other developed nations. Trump sent letters to 17 major companies in July demanding they slash U.S. prescription drug prices. Below is an overview of pharmaceutical companies which recently announced direct-to-consumer sales and price cuts in the U.S: PFIZER Pfizer and President Donald Trump said on Tuesday they had cut a deal in which the U.S.-based drugmaker agreed to lower prescription drug prices in the Medicaid programme to what it charges in other developed countries, in exchange for tariff relief. Pfizer will invest $70 billion in research and development and domestic manufacturing and received a three-year grace period during which its products will not be subject to U.S. tariffs on pharmaceuticals, Pfizer CEO Albert Bourla said. PhRMA U.S. pharmaceutical lobby group PhRMA said on Monday it would launch a new website, AmericasMedicines.com, next January to help patients buy prescription drugs directly from manufacturers. NOVO NORDISK Danish pharmaceutical company Novo Nordisk said in August that it would offer its diabetes drug Ozempic for $499 per month to eligible cash-paying patients with type 2 diabetes in the U.S. via its own pharmacy, a tie-up with telehealth service GoodRx and other platforms. It had announced earlier in April that it was working with telehealth firms Hims & Hers, Ro and LifeMD to sell Wegovy to cash-paying US customers. ELI LILLY Eli Lilly said in June it would ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website starting early August. ASTRA ZENECA AstraZeneca said on Friday it will sell its diabetes and asthma drugs direct to cash-paying U.S. patients at a discount of up to 70% off list prices. SANOFI French drugmaker Sanofi said on Friday it would offer a month’s supply of any of its insulin products for $35 to all patients in the U.S. with a valid prescription, regardless of insurance status. ROCHE Roche is considering selling its prescription medicines in the U.S. directly to consumers to bring costs down for patients, as part of talks with the U.S. government, CEO Thomas Schinecker said in July. The model could appeal not only to the uninsured or under-insured, but also to insured patients comparing the cost of accessing drugs through insurers with cash prices, an industry source told Reuters. ZEALAND PHARMA Zealand Pharma is considering a direct-to-patient sales model as well as traditional insurer channels for the experimental weight-loss drug it is developing with Roche, its CEO told Reuters in September. BRISTOL-MYERS SQUIBB U.S. pharmaceutical company Bristol-Myers Squibb will cut prices to eligible U.S. patients for blood clot treatment Eliquis and plaque psoriasis drug Sotyktu, with the latter being offered at a more than 80% discount to the list price, it said in September. WISP Women’s telehealth provider Wisp said in September it expanded its weight-care offerings to include sale and doorstep delivery of Novo Nordisk’s and Eli Lilly’s popular drugs without the need for insurance. It priced Ozempic, Wegovy, and Mounjaro at $598, $558, and $489 per month, respectively, with the cost also including consultation, monthly follow-ups, and direct-to-door delivery. ABBVIE AbbVie said on Monday it would launch its ovarian cancer drug Elahere in the UK at a list price matching that in the U.S. following Trump’s demands for drugmakers to offer the U.S. “most-favored-nation” pricing. Javi West Larraaga and Emanuele Berro, Reuters
Category:
E-Commerce
All news |
||||||||||||||||||
|
||||||||||||||||||